美国 · 股市与财经 · Investor's Business Daily

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

来源：Investor's Business Daily · 美国 12 小时前

Eli Lilly (LLY) already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market. The new contender, EloraTZP, helped patients with type 2…

在 Investor's Business Daily 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.investors.com)

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

推荐阅读

MetaMask exits Lido validators as it investigates security incident

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

EU Gas Crunch Forces Rethink of Methane Rules

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

分享

推荐阅读

MetaMask exits Lido validators as it investigates security incident

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

EU Gas Crunch Forces Rethink of Methane Rules